Autopsy report · NCT03690739

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

“Insufficient Recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 10 months before it started.
• Ran for about 1 year 7 months before it stopped.
• 9 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

AGO Research GmbH

Sponsor type

Industry

Conditions

Recurrent Ovarian Carcinoma

Interventions

Carboplatin; Gemcitabine; Bevacizumab; PLD; Paclitaxel; PLD

Participants

9

Sites

29

Countries

Germany

Trials that died the same way

• Preoperative Relaxation and Intensified Patient Surgery Education in Patients Undergoing Colorectal Surgery
  “Recruitment insufficient” (96% match in meaning)
• Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease
  “not enough recruitment” (91% match in meaning)
• Study SBX-01-101: A Stool Collection Study in Colorectal Cancer (CRC) Patients Treated With Irinotecan-Based Regimens
  “Insufficient recruitment population.” (91% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.